<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CHLORZOXAZONE - chlorzoxazone tablet </strong><br>Dispensing Solutions, Inc.<br></p></div>
<h1>CHLORZOXAZONE TABLETS, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_69bcae1d-d424-49b4-a69a-dbf3d09c5c09"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Revised SEPTEMBER 2002</span></p>
<p><span class="Bold">1005850104</span></p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_8d482fc1-1ba2-41dc-b050-182357298e99"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Each tablet contains:</p>
<p>Chlorzoxazone…………500 mg</p>
<p><span class="Bold">Inactive Ingredients:</span> Colloidal silicon dioxide, croscarmellose sodium, docusate sodium, lactose anhydrous, magnesium stearate, microcrystalline cellulose, sodium benzoate, D&amp;C yellow no. 10 aluminum lake, FD&amp;C blue no. 1 aluminum lake HT.</p>
<p>5-chloro-2-benzoxazolinone. The structural formula is as follows:</p>
<div class="Figure">
<img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b91e3ba-1eb6-4297-9d1b-28d87b36a5b3&amp;name=277383c8-d578-44d3-9f7f-93c38204ed98-01.jpg"><p class="MultiMediaCaption">C<span class="Sub">7</span>H4ClNO2            Molecular Weight:169.57</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_c070f962-b661-43cb-953a-5e78c9be16fe"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">Chlorzoxazone is a centrally-acting agent for painful musculoskeletal conditions. Data available from animal experiments as well as human study indicate that chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multi-synaptic reflex arcs involved in producing and maintaining skeletal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span> of varied etiology. The clinical result is a reduction of the skeletal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span> with relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and increased mobility of the involved muscles. Blood levels of chlorzoxazone can be detected in people during the first 30 minutes and peak levels may be reached, in the majority of the subjects, in about 1 to 2 hours after oral administration of chlorzoxazone. Chlorzoxazone is rapidly metabolized and is excreted in the urine, primarily in a conjugated form as the glucuronide. Less than one percent of a dose of chlorzoxazone is excreted unchanged in the urine in 24 hours.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_c8d94a83-4b8c-4250-96bd-d10e85d1ac63"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">Chlorzoxazone tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> associated with acute painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified but may be related to its sedative properties. Chlorzoxazone does not directly relax <span class="product-label-link" type="condition" conceptid="4136244" conceptname="Feeling tense">tense</span> skeletal muscles in man.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_3b67f6c2-c16e-41df-bdbb-aab80e866476"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Chlorzoxazone tablets are contraindicated in patients with known intolerance to the drug.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_319e8db4-edf7-424b-af9b-cdc928c9496b"></a><a name="section-6"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">Serious (including fatal) hepatocellular toxicity has been reported rarely in patients receiving chlorzoxazone. The mechanism is unknown but appears to be idiosyncratic and unpredictable. Factors predisposing patients to this rare event are not known. Patients should be instructed to report early signs and/or symptoms of hepatotoxicity such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">right upper quadrant pain</span>, dark urine, or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. Chlorzoxazone should be discontinued immediately and a physician consulted if any of these signs or symptoms develop. Chlorzoxazone use should also be discontinued if a patient develops abnormal liver enzymes (e.g., AST, ALT, alkaline phosphatase and bilirubin).</p>
<p>The concomitant use of alcohol or other central nervous system depressants may have an additive effect.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0ce528b0-62a3-4ae2-b1f2-04eba0413a2f"></a><a name="section-6.1"></a><p></p>
<h2>Usage in Pregnancy:</h2>
<p class="First">The safe use of chlorzoxazone has not been established with respect to the possible adverse effects upon fetal development. Therefore, it should be used in women of childbearing potential only when, in the judgment of the physician, the potential benefits outweigh the possible risks.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_c160598a-43c8-43cb-b117-0cf4f28413c3"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS:</h1>
<p class="First">Chlorzoxazone should be used with caution in patients with known allergies or with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to drugs. If a sensitivity reaction occurs such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the skin, the drug should be stopped.</p>
<p>If any symptoms suggestive of liver dysfunction are observed, the drug should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_33f1c86f-2cf4-4a33-a4f3-128aa89cd251"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">After extensive clinical use of chlorzoxazone-containing products, it is apparent that the drug is well-tolerated and seldom produces undesirable side effects. Occasional patients may develop <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>. It is possible in rare instances that chlorzoxazone may have been associated with <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, or overstimulation may be noted by an occasional patient. Rarely, allergic-type <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, or <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span> may develop during treatment. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioneurotic edema</span> or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> are extremely rare. There is no evidence that the drug will cause renal damage. Rarely, a patient may note discoloration of the urine resulting from a phenolic metabolite of chlorzoxazone. This finding is of no known clinical significance.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_ca1d8bf5-7b0c-4fce-b65d-0da71c772944"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE:</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f86b7cda-d209-438b-81f2-0f06f27adfce"></a><a name="section-9.1"></a><p></p>
<h2>Symptoms:</h2>
<p class="First">Initially, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> together with <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> may occur. Early in the course there may be <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> or <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">sluggishness</span> followed by marked loss of muscle tone, making voluntary movement impossible. The deep tendon reflexes may be decreased or absent. The sensorium remains intact, and there is no peripheral <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">loss of sensation</span>. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> may occur with rapid, irregular respiration and intercostal and substernal retraction. The blood pressure is lowered, but <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> has not been observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bbb885d7-aecd-4011-afbd-f45b3f8669f4"></a><a name="section-9.2"></a><p></p>
<h2>Treatment:</h2>
<p class="First">Gastric lavage or induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> should be carried out, followed by administration of activated charcoal. Thereafter, treatment is entirely supportive. If respirations are depressed, oxygen and artificial respiration should be employed and a patent airway assured by use of an oropharyngeal airway or endotracheal tube. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> may be counteracted by use of dextran, plasma, concentrated albumin or a vasopressor agent such as norepinephrine. Cholinergic drugs or analeptic drugs are of no value and should not be used.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_b02d3fa5-c33e-4e4b-ac6c-341f3f8dbaf7"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_937d4092-871a-42a9-a072-09fa52a54a80"></a><a name="section-10.1"></a><p></p>
<h2>Usual Adult Dosage:</h2>
<p class="First">One tablet three or four times daily. If adequate response is not obtained with this dose, it may be increased to 1½ tablets (750 mg) three or four times daily. As improvement occurs dosage can usually be reduced.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_cc27cd80-ad1e-43be-b556-8b905d13d59e"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Chlorzoxazone Tablets, USP are available as:</p>
<a name="id_bd6283b1-26c6-4cd2-98fc-4a7d4b491e0e"></a><table width="431.000">
<col width="20.2%">
<col width="79.8%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top">500 mg:</td>
<td class="Botrule" align="left" valign="top">Light green, round, scored tablet. Debossed with 555/585 on one side and stylized<span class="Bold"> barr</span> on the other side. Available in bottles of:</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top">20 NDC 0555-0585-18</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top">100 NDC 0555-0585-02</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top">500 NDC 0555-0585-04</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule" align="left" valign="top">1000 NDC 0555-0585-05</td>
</tr>
</tbody>
</table>
<p>Dispense with a child-resistant closure in a tight container as defined in the USP/NF.</p>
<p>Store at controlled room temperature 15º-30ºC (59º-86ºF) [See USP].</p>
<p><span class="Bold">MANUFACTURED BY</span></p>
<p><span class="Bold">BARR LABORATORIES, INC.</span></p>
<p><span class="Bold">POMONA, NY 10970</span></p>
<p>Revised SEPTEMBER 2002</p>
<p>BR-585</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_729e5e63-608f-4d3b-9b93-354a9fa387d3"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="NDC 55045-1594-08" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3b91e3ba-1eb6-4297-9d1b-28d87b36a5b3&amp;name=NDC%2055045-1594-08------Barr%20Laboratories,%20Inc.jpg"></div>
<br><br>NDC 55045-1594-08<br><br>Chlorzoxazone<br><br>Tablets, USP<br><br>500 mg<br><br>Rx only<br><br>100 Tablets<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CHLORZOXAZONE 		
					</strong><br><span class="contentTableReg">chlorzoxazone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55045-1594(NDC:0555-0585)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CHLORZOXAZONE</strong> (CHLORZOXAZONE) </td>
<td class="formItem">CHLORZOXAZONE</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DOCUSATE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">green (light green) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">555;585;barr</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55045-1594-8</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA089895</td>
<td class="formItem">01/16/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Dispensing Solutions, Inc.
							(066070785)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Dispensing Solutions, Inc.</td>
<td class="formItem"></td>
<td class="formItem">066070785</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d223d18e-6d76-4a00-8c63-6ee0be2110bc</div>
<div>Set id: 3b91e3ba-1eb6-4297-9d1b-28d87b36a5b3</div>
<div>Version: 1</div>
<div>Effective Time: 20110907</div>
</div>
</div> <div class="DistributorName">Dispensing Solutions, Inc.</div></p>
</body></html>
